Growth Metrics

Novartis Ag (NVS) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 169.93%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -52.86%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -45.83%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -185.57%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 4.37%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 54.81%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -9.62%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 9.17%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -12.14%
Dec 31, 2024 2,462.27%
Jun 30, 2024 3,049.31%
Dec 31, 2023 -15.60%
Sep 30, 2023 -22.84%
Jun 30, 2023 -98.54%
Mar 31, 2023 -76.28%
Dec 31, 2022 -90.20%
Sep 30, 2022 -39.19%
Jun 30, 2022 5.80%
Mar 31, 2022 6.40%
Dec 31, 2021 -59.82%
Sep 30, 2021 -18.96%
Jun 30, 2021 -14.11%
Mar 31, 2021 176.59%
Mar 31, 2020 253.66%
Mar 31, 2019 -292.47%
Dec 31, 2018 -103.06%
Sep 30, 2018 -121.75%
Jun 30, 2018 -99.56%
Mar 31, 2018 -90.76%
Dec 31, 2017 4,818.60%
Sep 30, 2017 10.71%
Jun 30, 2017 273.55%
Mar 31, 2017 239.24%
Dec 31, 2016 362.12%
Sep 30, 2016 546.75%
Jun 30, 2016 3,111,111,211.11%
Mar 31, 2016 39,888,955.24%
Dec 31, 2015 311,552.19%
Sep 30, 2015 81,836,440.75%
Jun 30, 2015 82.09%
Mar 31, 2015 4.20%
Sep 30, 2014 -64.37%
Jun 30, 2014 -246.98%
Sep 30, 2013 -33.64%
Jun 30, 2013 -113.15%
Sep 30, 2012 7.64%
Jun 30, 2012 -41.90%
Mar 31, 2012 -6.64%
Dec 31, 2011 123.38%
Sep 30, 2011 -12.25%
Jun 30, 2011 13.15%
Mar 31, 2011 -78.46%
Dec 31, 2010 43,124.10%
Sep 30, 2010 53,341.51%
Jun 30, 2010 44,070.37%
Mar 31, 2010 272,511.35%